Article
Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics.
Phil Challis, vice-president of product development at eTheRNA, discusses four of the major challenges in working with mRNA therapeutics. Some topics he touches on include; what makes a good RNA construct; making RNA more tolerable; storage and distribution of lipid nanoparticles; and more.
For more INTERPHEX 2023 video content, check this page for updates.
Stay at the forefront of biopharmaceutical innovation—subscribe to BioPharm International for expert insights on drug development, manufacturing, compliance, and more.